Disease · MONDO_0005454
lung neuroendocrine neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lung neuroendocrine neoplasm. Diseases, record MONDO_0005454. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005454
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
lung NET, lung neuroendocrine tumor, lung neuroendocrine tumor, well differentiated, low or intermediate grade, lung neuroendocrine tumour, neuroendocrine neoplasm of lung, neuroendocrine neoplasm of the lung, pulmonary neuroendocrine neoplasm, pulmonary neuroendocrine tumor
- Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUTETIUM LU177 EDOTREOTIDE | CHEMBL5095425 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADEBRELIMAB | CHEMBL4297828 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CABOZANTINIB | CHEMBL2105717 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVOCERANIB | CHEMBL3186534 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SELINEXOR | CHEMBL3545185 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SURUFATINIB | CHEMBL4297190 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets18
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 1/2 | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 1/2 | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 1/2 | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR4 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 1/2 | https://conductscience.org/library/genes/6754 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 2 | Somatostatin receptor agonist; Somatostatin receptor binding agent | Phase 1/2 | https://conductscience.org/library/genes/6755 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor 1 | 1 | Fibroblast growth factor receptor 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
1 to 10 of 18
See all 18 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Phase 1/2 | 89 | 2021-12-14 | Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma | NENDRATAREOTIDE UZATANSINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Phase 1/2 | 9 | 2021-03-16 | Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | NIVOLUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT07357623 | Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors | Phase 2 | 96 | Pulmonary Neuroendocrine Tumor | CAPECITABINE, CARBOPLATIN, ETOPOSIDE, SURUFATINIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | Phase 2 | 39 | Neuroendocrine Tumors | ADEBRELIMAB, RIVOCERANIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04893785 | A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) | Phase 2 | 35 | Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor | CABOZANTINIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01175096 | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | Phase 1/2 | 20 | Neuroendocrine Tumors, Carcinoid Tumor | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT01324492 | Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | Phase 1 | 16 | Lung Neuroendocrine Neoplasm | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Phase 2 | 14 | Carcinoma, Neuroendocrine | SELINEXOR | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phase I - Dose Level -1 vs Phase I - Dose Level 0: Number of Participants With Treatment Related Adverse Events | 3 of 3 | 6 of 6 | 9 | NCT03325816 | Trial comparisons |
| Phase I - Dose Level -1 vs Phase I - Dose Level 0: deaths from any cause | 0 of 3 | 0 of 6 | 9 | NCT03325816 | Trial comparisons |
| Phase I - Dose Level -1 vs Phase I - Dose Level 0: serious adverse events | 2 of 3 | 2 of 6 | 9 | NCT03325816 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005454
GET https://conductscience.org/api/diseases/v1/MONDO_0005454/drugs